Gigolaeva 2019.

Study characteristics
Methods	Accrual: not reported Single centre Phase of trial: not reported Study design: RCT Country or countries where the trial was conducted: Russia Median follow‐up: not reported
Participants	Age: median 47, range 32–62 years Nodal status of breast cancer: not reported Adjuvant or neoadjuvant: neoadjuvant Notable exclusion criteria: not reported
Interventions	Arm 1: doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles followed by carboplatin AUC2 weekly + eribulin 1.4 mg/m2 OR paclitaxel 175 mg/m2 every 3 weeks for 12 weeks Arm 2: doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles followed by paclitaxel 80 mg/m2 for 12 weeks
Outcomes	Primary pCR, according to Miller‐Payne grading system (i.e. grade 5 where no malignant cells were identified at the site of the tumour, DCIS may be present) Secondary: none reported
Notes	Trial registration record could not be found. Abstract only available. Full article has not yet been published. Contact details for the authors could not be found to request an update on results or published works. Funding considerations: "no significant conflicts of interest" (p.S70) declared in the abstract.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "A randomized prospective study" … "randomization (2:1)." No additional details were provided in the abstract.
Allocation concealment (selection bias)	Unclear risk	Method of concealment was not described in the abstract.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No information provided in the abstract.
Blinding of outcome assessment (detection bias): neoadjuvant studies only: pCR	Unclear risk	No information provided on tests used or process to evaluate response.
Selective reporting (reporting bias)	Unclear risk	Unable to assess from the abstract. A trial registration record could not be found.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No reporting of attrition or exclusions in the available abstract.
Other bias	Unclear risk	Unable to assess from the abstract.